49th Annual Meeting of Korean Cancer Association &
9th International Cancer Conference

Program

Korea Standard Time
Local Time

Invited Speakers




Plenary Lectures (PL)
Shimon Sakaguchi CV
Immunology Frontier Research Center, Osaka University, Japan
Targeting tumor-infiltrating Tregs as a cancer immunotherapy
David Tuveson CV
Cold Spring Harbor Laboratory Cancer Center, USA
The seven deadly hallmarks of pancreatic cancer
Yoon-Koo Kang CV
University of Ulsan College of Medicine
Adjuvant treatment of resectable gastric cancer. Where are we now in Asia?
Charles Swanton CV
Francis Crick Institute & UCL Cancer Institute, UK
Mechanism of action and inflammatory axis for air pollution induced non-small cell lung cancer


Educational Sessions (ES)

ES1. Single-cell multiomics
6/15(Thu) 09:00-10:40
cv
Heetak Lee
Institute for Basic Science
cv
Woong-Yang Park
Samsung Genome Institute
cv
Amos Chungwon Lee
Seoul National University College of Engineering
cv
Hye Ryun Kim
Yonsei University College of Medicine

ES2. Population science and early cancer detection
6/15(Thu) 09:00-10:40
cv
Kyu Won Jung
National Cancer Center
cv
Aesun Shin
Seoul National University College of Medicine
cv
Duhee Bang
Yonsei University College of Science

ES3. Liquid biopsy and extracelluar vesicles
6/15(Thu) 09:00-10:40
cv
Nobuaki Matsubara
National Cancer Center Hospital East, Japan
cv
Jae Myoung Noh
Sungkyunkwan University School of Medicine
cv
Han Sang Kim
Yonsei University College of Medicine

ES4. Engineering antibody and drug conjugates for cancer therapy
6/15(Thu) 13:20-15:00
cv
Chang-Han Lee
Seoul National University
cv
Chul Kim
Georgetown Lombardi Comprehensive Cancer Center, USA
cv
Chul-Woong Chung
LegoChem Biosciences
cv
Sang Jeon Chung
Sungkyunkwan University School of Pharmacy

ES5. Novel cellular and gene-editing therapies
6/15(Thu) 15:20-17:00
cv
Chungyong Han
National Cancer Center
cv
Dok Hyun Yoon
University of Ulsan College of Medicine
cv
Hyun Jung Chung
Korea Advanced Institute of Science and Technology
cv
Tae-Don Kim
Korea Research Institute of Bioscience and Biotechnology

ES6. Practical consideration for perioperative treatment
6/16(Fri) 15:20-17:00
cv
Juhee Cho
Sungkyunkwan University
cv
Gyungyub Gong
University of Ulsan College of Medicine
cv
Jee Hyun Kim
Seoul National University College of Medicine
cv
Eun Joo Kang
Korea University College of Medicine

ES7. Spatial biology for cancer research
6/16(Fri) 15:20-17:00
cv
Quan Nguyen
The University of Queensland, Australia
cv
Sunghoon Kwon
Seoul National University College of Engineering
cv
Tae Hyun Hwang
Mayo Clinic, USA
cv
Kwon Joong Na
Seoul National University College of Medicine


Symposia (SP)

SP01. Cutting-edge technologies for immunotherapy
* Joint Symposium of KCA & Japanese Cancer Association (JCA)
6/15(Thu) 13:20-15:00
cv
Yong Taik Lim
Sungkyunkwan University College of Engineering
cv
Koji Tamada
Yamaguchi University, Japan
cv
Yong-Sung Kim
Ajou University College of Engineering
cv
Shohei Koyama
National Cancer Center, Japan

SP02. Updates on oligometastasis
6/15(Thu) 13:20-15:00
cv
C. Jillian Tsai
University Health Network, Canada
cv
Won Kyung Cho
Samsung Medical Center
cv
Jun Won Um
Korea University College of Medicine
cv
Myung-Ah Lee
The Catholic University of Korea College of Medicine
cv
Eui Kyu Chie
Seoul National University College of Medicine

SP03. Overcome resistance to immunotherapy
Joint Symposium of KCA & Korean Association of Immunologists (KAI)
6/15(Thu) 15:20-17:00
cv
Tae Woo Kim
Korea University College of Medicine
cv
Se-Hoon Lee
Sungkyunkwan University School of Medicine
cv
Heung Kyu Lee
Korea Advanced Institute of Science and Technology
cv
Kyong Hwa Park
Korea University College of Medicine

SP04. Understanding tumor ecosystems
Joint Symposium of KCA & Korea Genome Organization (KOGO)
6/15(Thu) 15:20-17:00
cv
Jong-Eun Park
Korea Advanced Institute of Science and Technology
cv
Takatsugu Ishimoto
Kumamoto University, Japan
cv
Jae-Seok Roe
Yonsei University College of Life Science & Biotechnology
cv
Tae-Min Kim
The Catholic University of Korea College of Medicine

SP05. 암 정보 현황과 정책 방향
6/15(Thu) 15:20-17:00
cv
Nam Soo Byeon
Korea Health Information Service
cv
Kui Son Choi
National Cancer Center
cv
Hyun-Young Park
Korea National Institute of Health
cv
Seon-Young Kim
Korea Research Institute of Bioscience and Biotechnology

SP06. Real-world clinico-genomic data
6/16(Fri) 09:00-10:00
cv
Jürgen Wolf
University Hospital of Cologne, Germany
cv
Sung Gwe Ahn
Gangnam Severance Hospital
cv
Sheehyun Kim
Seoul National University Hospital

SP07. Novel treatment for pediatric CNS tumors
6/16(Fri) 09:00-10:00
cv
Se Hoon Kim
Yonsei University College of Medicine
cv
Jung Yoon Choi
Seoul National University College of Medicine
cv
Do-Hyun Nam
Sungkyunkwan University School of Medicine

SP08. Cancer genomics
* Joint Symposium of KCA & Cancer Science Institute of Singapore (CSI Singapore)
6/16(Fri) 13:20-15:00
cv
Jung Kyoon Choi
Korea Advanced Institute of Science and Technology
cv
Wai Leong Tam
CSI Singapore & National University of Singapore, Singapore
cv
Hyunsook Lee
Seoul National University College of Natural Sciences
cv
Yvonne Tay
CSI Singapore, National University of Singapore, Singapore

SP09. Increasing the therapeutic ratio of radiotherapy using biochemical combination
6/16(Fri) 13:20-15:00
cv
BuHyun Youn
Pusan National University
cv
Taeghwan Hyeon
Seoul National University College of Engineering
cv
Jae-Sung Kim
Korea Institute of Radiological & Medical Sciences
cv
Chunlin Shao
Fudan University, China

SP10. Changing clinical practice in gynecologic cancer: Current status and future perspective
Joint Symposium of KCA & Korean Society of Gynecologic Oncology (KSGO)
6/16(Fri) 13:20-15:00
cv
Jung-Yun Lee
Yonsei University College of Medicine
cv
Sook-hee Hong
The Catholic University of Korea College of Medicine
cv
Won Kyung Cho
Samsung Medical Center
cv
Sung Il Hwang
Seoul National University Bundang Hospital

SP11. 국립암센터 항암신약치료개발사업단 임상개발 현황
6/16(Fri) 13:20-15:00
cv
Joong-Won Park
National Cancer Center
cv
Hark Kyun Kim
National Cancer Center
cv
Jungwon Woo
Genexine
cv
Joong Won Lee
Eutilex Co., Ltd.

SP12. Current advance of multidisciplinary management in HCC
* Joint Symposium of KCA & China Anti-Cancer Association (CACA)
6/16(Fri) 15:20-17:00
cv
Dandan Hu
Sun Yat-Sen University Cancer Center, China
cv
Pil Soo Sung
The Catholic University of Korea College of Medicine
cv
Tianqiang Song
Tianjin Medical University Cancer Institute & Hospital, China
cv
Hong Jae Chon
CHA University School of Medicine

SP13. 암관련학회협의체 심포지엄: 암정밀의료에서 NGS의 역할
6/16(Fri) 15:20-17:00
cv
Shinkyo Yoon
University of Ulsan College of Medicine
cv
SeungEun Kim
Novartis
cv
Sun Young Kim
Asan Medical Center


Special Lecture (SL)

Next-generation approaches to discovering therapeutics and therapeutic targets in cancer
6/16(Fri) 09:30-10:00
cv
William R. Sellers
Broad Institute, USA


Young Investigator Symposium (YIS)

Young Investigator Symposium
6/16(Fri) 09:00-10:10
cv
June-Koo Lee
Memorial Sloan-Kettering Cancer Center, USA
cv
Jung Yong Hong
Sungkyunkwan University College of Medicine
cv
Joo Ho Lee
Seoul National University College of Medicine


Luncheon Symposia (LS)

Luncheon Symposium 1 (MSD)
6/15(Thu) 12:20-13:00
Gun Min Kim CV
Yonsei University College of Medicine
Blossom women's more TOMMOROWs with pembrolizumab
Luncheon Symposium 2 (Roche)
6/15(Thu) 12:20-12:40
Sun Min Lim CV
Yonsei University College of Medicine
Illuminating the path forward in early stage NSCLC:
Unmet needs and the evolving treatment landscape (IMP010)
Luncheon Symposium 3 (Novartis)
6/15(Thu) 12:20-12:40
Hye Sung Won CV
The Catholic University of Korea College of Medicine
Clinical considerations for ribociclib treatment in HR+HER2-mBC patients
Luncheon Symposium 4 (Boryung)
6/16(Fri) 11:40-12:20
Beung-Chul Ahn CV
National Cancer Center
New approches for treatment of small cell lung cancer
Luncheon Symposium 5 (ONO/BMS)
6/16(Fri) 11:40-12:20
Woo Kyun Bae CV
Chonnam National University Medical School
IO in GC/GEJ/EAC 1L with 3y long-term data
Luncheon Symposium 6 (Lilly)
6/16(Fri) 11:40-12:20
Keun Seok Lee CV
National Cancer Center
Take hope further for HR+HER2- high-risk early breast cancer patients with abemiciclib

top